How training and reduction of antispastic medication affects adults with severe cerebral palsy

ISRCTN ISRCTN66528622
DOI https://doi.org/10.1186/ISRCTN66528622
Secondary identifying numbers 1A
Submission date
23/06/2020
Registration date
24/06/2020
Last edited
20/07/2021
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Cerebral palsy (CP) is caused by an injury to the immature brain that disturbs typical development. People with CP often have reduced muscle strength and difficulties in learning motor (movement) activities. This may impact their ability to perform activities such as standing, walking, running and participation in everyday life. Traditional treatment consists of physiotherapy and efforts to normalize movements. People with CP are often treated with antispastic treatment, but this medication may cause inactivity because of side effects such as drowsiness, muscle weakness and impaired motor learning. There is very little research regarding physical interventions in adults with CP, especially the severy affected. This study therefore aims to investigate if adults who are severely affected by CP are able to improve their motor function through tailored training supported by a reduction in their antispastic medication.

Who can participate?
Adults aged over 18 with CP

What does the study involve?
Participants are assigned to three different groups. The first group receives a 3-month physical intervention (3-5 times per week over 12 weeks) and discontinued antispastic medication (oral bachlofen or dantrolene). The second group receives an intervention including standard care and discontinued antispastic medication. The third group functions as a control group including standard care and no changes to medication. Participants' functional ability is measured at the start of the study, immediately after the 4-week drug discontinuation, immediately after the 12-week active intervention, and at follow-up 1 month after finishing the intervention.

What are the possible benefits and risks of participating?
Participants in the intervention group may benefit from better physical function and health. No risks are expected, except for occasionally muscle soreness. Participants whose antispastic medication is reduced may experience fewer side effects. Reduction of medication is evaluated individually and an experienced physician will oversee the process. Information obtained from this study may benefit future rehabilitation approaches and individualized training methods for adults with severe brain damage.

Where is the study run from?
Jonstrupvang Bebyggelsen (Denmark)

When is the study starting and how long is it expected to run for?
September 2018 to September 2022

Who is funding the study?
The Elsass Foundation (Denmark)

Who is the main contact?
Helle Hüche Larsen
hhl@elsassfonden.dk

Contact information

Miss Helle Hüche Larsen
Scientific

Panum Institute 33.3
Blegdamsvej 3
Copenhagen
2200
Denmark

Phone +45 (0)26573438
Email hhl@elsassfonden.dk
Miss Helle Hüche Larsen
Public

Panum Institute 33.3
Blegdamsvej 3
Copenhagen
2200
Denmark

Phone +45 (0)26573438
Email hhl@elsassfonden.dk

Study information

Study designOpen-label non-randomized pragmatic clinical pilot study with a two-group design
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Home
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a participant information sheet
Scientific titleEffect of motor learning-based activities combined with discontinuation of antispastic medication on functional ability in adults with severe cerebral palsy
Study objectivesGross motor function in adults with severe cerebral palsy can be optimized by daily motor-learning based activities combined with discontinuation in antispastic medication.
Ethics approval(s)Approved 07/09/2018, Center For Sundhed (Regionsgården, Kongens Vænge 2, 3400 Hillerød; +45 (0)38666395; vek@regionh.dk), ref: H-18029151
Health condition(s) or problem(s) studiedGross motor function in cerebral palsy
InterventionAdults with severe CP (Gross Motor Function Classification Scale III-V) are recruited through convenience sampling and assigned to three different groups:
1. The first group receives a 3-month physical intervention including activities based on motor learning principles and discontinued antispastic medication (oral bachlofen or dantrolene)
2. The second group receives an intervention including standard care and discontinued antispastic medication
3. The third group functions as a control group including standard care and no changes to medication

The physical intervention is planned based on science-based neurorehabilitation and motor learning principles and adjusted individually to each participant. The dose will be 3-5 times per week in 12 weeks.

Participants will be reduced in bachlofen or dantrolene dose by 25% per week during a 4-week period. In this period participants are closely followed by an experienced physician.

Participants will be enrolled through convenience sampling and are distinguished by their willingness to participate and therefore not randomly assigned to groups.
Intervention typeMixed
Primary outcome measureFunctional ability measured by Gross Motor Function Measure (GMFM-88) at baseline; immediately following 4-week drug discontinuation and prior to starting the 12-week active intervention; immediately following the intervention; and at follow-up 1 month after finishing the intervention
Secondary outcome measuresNeurological screening including Modified Ashworth's Scale (MAS), Range of Motion (ROM), tendon reflex testing and 0-5 strength scale at baseline; immediately following 4-week drug discontinuation and prior to starting the 12-week active intervention; immediately following the intervention; and at follow-up 1 month after finishing the intervention
Overall study start date01/09/2018
Completion date01/09/2022

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants30
Total final enrolment16
Key inclusion criteria1. Diagnosed with cerebral palsy
2. GMFCS level between III-V
3. >18 years of age
Key exclusion criteriaDoes not meet inclusion criteria
Date of first enrolment12/09/2018
Date of final enrolment08/03/2020

Locations

Countries of recruitment

  • Denmark

Study participating centre

Jonstrupvang Bebyggelsen
Chr. Hauchs Alle 11
Værløse
3500
Denmark

Sponsor information

University of Copenhagen
University/education

Panum Institute 33.3
Blegdamsvej 3
Copenhagen
2200
Denmark

Phone +45 (0)26573438
Email hellel1@hotmail.com
Website http://www.ku.dk/english/
ROR logo "ROR" https://ror.org/035b05819

Funders

Funder type

Charity

Elsass Fonden
Private sector organisation / Trusts, charities, foundations (both public and private)
Alternative name(s)
Elsass Foundation
Location
Denmark

Results and Publications

Intention to publish date01/01/2021
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal
IPD sharing planThe datasets generated during and/or analysed during the current study are/will be available upon request from Helle Hüche Larsen (hhl@elsassfonden.dk). Participants gave written informed consent to the study, which was approved by the local ethics committee of Copenhagen region and performed in accordance with the Helsinki Declaration. All personal data are anonymized. Files containing personal data are stored on a separate hard drive and stored securely according to the guidelines provided by The Danish Data Protection Agency. Raw data will be available in anonymized form on request for statistical or scientific purposes of significant meaning according to the guidelines provided by The Danish Data Protection Agency.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article 30/04/2021 20/07/2021 Yes No

Editorial Notes

20/07/2021: Publication reference added.
24/06/2020: Trial's existence confirmed by Center For Sundhed.